Your browser is no longer supported. Please, upgrade your browser.
Settings
FLDM Fluidigm Corporation daily Stock Chart
FLDM [NASD]
Fluidigm Corporation
Index- P/E- EPS (ttm)-1.49 Insider Own0.60% Shs Outstand68.15M Perf Week-7.03%
Market Cap874.36M Forward P/E- EPS next Y-0.74 Insider Trans273.86% Shs Float68.15M Perf Month-10.65%
Income-59.00M PEG- EPS next Q-0.28 Inst Own55.40% Short Float2.51% Perf Quarter48.32%
Sales113.00M P/S7.74 EPS this Y18.90% Inst Trans-23.91% Short Ratio2.01 Perf Half Y56.65%
Book/sh1.74 P/B7.37 EPS next Y21.30% ROA-21.80% Target Price14.60 Perf Year109.30%
Cash/sh1.40 P/C9.17 EPS next 5Y-8.06% ROE-132.70% 52W Range4.65 - 14.90 Perf YTD48.84%
Dividend- P/FCF- EPS past 5Y-18.10% ROI-18.70% 52W High-13.89% Beta2.42
Dividend %- Quick Ratio3.00 Sales past 5Y9.70% Gross Margin54.60% 52W Low175.91% ATR0.64
Employees505 Current Ratio3.40 Sales Q/Q16.60% Oper. Margin-42.70% RSI (14)46.24 Volatility4.03% 4.63%
OptionableYes Debt/Eq2.39 EPS Q/Q-32.00% Profit Margin-52.20% Rel Volume0.50 Prev Close13.05
ShortableYes LT Debt/Eq2.39 EarningsMay 02 AMC Payout- Avg Volume851.64K Price12.83
Recom2.00 SMA20-4.75% SMA505.56% SMA20046.12% Volume429,879 Change-1.69%
Mar-15-19Initiated UBS Neutral $14
Jan-03-19Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated Mizuho Buy $11 → $12
Aug-05-16Reiterated Cantor Fitzgerald Buy $13 → $11
May-05-16Reiterated Mizuho Buy $8 → $11
Apr-12-16Reiterated Leerink Partners Outperform $20 → $15
Jan-07-16Initiated Deutsche Bank Buy $18
Oct-30-15Upgrade Cantor Fitzgerald Hold → Buy $15 → $12
Oct-30-15Reiterated Mizuho Neutral $15 → $8
Aug-27-15Initiated Cantor Fitzgerald Hold
Aug-07-15Reiterated Mizuho Neutral $30 → $15
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
May-08-15Reiterated Maxim Group Buy $52 → $44
May-08-15Downgrade Mizuho Buy → Neutral $50 → $30
May-06-14Reiterated Maxim Group Buy $65 → $52
Apr-23-14Upgrade Mizuho Neutral → Buy $43 → $50
Mar-21-14Reiterated Maxim Group Buy $52 → $65
Feb-03-14Reiterated Oppenheimer Outperform $46 → $52
Jan-14-14Reiterated Mizuho Neutral $30 → $43
Apr-08-19 03:55PM  How Should Investors Feel About Fluidigm Corporation's (NASDAQ:FLDM) CEO Pay? Simply Wall St.
02:49PM  3 Stocks to Hold for the Next 20 Years Motley Fool
Apr-05-19 09:40AM  Here's Why You Should Invest in DENTSPLY (XRAY) Stock Now Zacks
Apr-04-19 04:05PM  Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results GlobeNewswire
Apr-03-19 10:32AM  AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates Zacks
Apr-02-19 10:20AM  Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition Zacks
10:20AM  AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study Zacks
Mar-28-19 08:45AM  Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting GlobeNewswire
08:30AM  Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry GlobeNewswire
Mar-27-19 09:42AM  Look who leased the top floors of South San Francisco's new biotech highrise American City Business Journals
Mar-18-19 05:48PM  Fluidigm Corp (FLDM) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-15-19 08:51AM  Fluidigm (FLDM) in Focus: Stock Moves 8% Higher Zacks
Mar-14-19 11:53AM  Here's Why Fluidigm Rose as Much as 13.4% Today Motley Fool +7.97%
Mar-12-19 09:54AM  Fluidigm Is Emerging From a Large Base Pattern, So Go Long TheStreet.com
Mar-08-19 07:47AM  3 Top Stocks Under $20 Motley Fool
Mar-05-19 08:30AM  Colin McCracken Joins Fluidigm as Chief Commercial Officer GlobeNewswire
Feb-22-19 05:30PM  Fluidigm to Participate in Upcoming Investor Conferences GlobeNewswire
02:33PM  Edited Transcript of FLDM earnings conference call or presentation 7-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-19-19 02:00PM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
08:00AM  Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-12-19 07:00PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
02:23PM  Fluidigm Corporation (NASDAQ:FLDM): Is It A Good Long Term Opportunity? Simply Wall St.
Feb-11-19 05:03PM  The 1 Stock I'd Buy Right Now Motley Fool
Feb-08-19 03:55PM  Here's Why Fluidigm Rose as Much as 14.2% Today Motley Fool +9.36%
Feb-07-19 08:09PM  Fluidigm Corp (FLDM) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:50PM  Fluidigm (FLDM) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:57PM  Fluidigm: 4Q Earnings Snapshot Associated Press
04:05PM  Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
09:00AM  Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations GlobeNewswire
08:30AM  Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases GlobeNewswire
Jan-31-19 08:30AM  Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1 GlobeNewswire
Jan-24-19 07:55AM  Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-14-19 04:05PM  Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Jan-08-19 08:30AM  Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring GlobeNewswire +5.03%
Dec-23-18 09:49PM  Do Hedge Funds Love Fluidigm Corporation (FLDM)? Insider Monkey
Dec-14-18 04:05PM  Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Dec-12-18 01:01AM  Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock GlobeNewswire
Dec-11-18 04:01PM  Fluidigm Announces Commencement of Public Offering of Common Stock GlobeNewswire
Dec-10-18 04:23PM  Edited Transcript of FLDM earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents
Dec-05-18 09:15AM  Recent Gains Cut in Half on Trade, Yield Curve Fears Zacks
Nov-12-18 04:05PM  Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire -5.24%
Nov-09-18 04:05PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-08-18 08:30AM  Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018 GlobeNewswire
Nov-07-18 04:11PM  Fluidigm Recognized as a Company to Watch in 2019 GlobeNewswire +6.15%
Nov-06-18 08:35AM  Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-01-18 07:50PM  Fluidigm (FLDM) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:43PM  Fluidigm: 3Q Earnings Snapshot Associated Press
04:05PM  Fluidigm Announces Third Quarter 2018 Financial Results GlobeNewswire
08:30AM  Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development GlobeNewswire
Oct-31-18 08:30AM  Laura Clague Named to Fluidigm Board of Directors GlobeNewswire
Oct-25-18 08:30AM  Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System GlobeNewswire
Oct-16-18 07:45AM  Market Trends Toward New Normal in Globant S.A, EZCORP, Earthstone Energy, SPX, Fluidigm, and MAG Silver Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-04-18 08:30AM  Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD GlobeNewswire
Oct-01-18 04:15PM  Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results GlobeNewswire
Sep-27-18 04:05PM  Fluidigm Introduces Single-Cell Total RNA Sequencing Applications for C1 GlobeNewswire
Sep-10-18 08:30AM  Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis GlobeNewswire
Sep-07-18 07:30AM  Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD GlobeNewswire
Sep-05-18 06:00PM  Fluidigm to Participate at Upcoming Investor Events in September GlobeNewswire
Aug-15-18 07:45AM  Detailed Research: Economic Perspectives on Middlesex Water, Farmer Brothers, Fluidigm, QCR, Revlon, and Gladstone Land What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-09-18 08:30AM  Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting GlobeNewswire
Aug-06-18 04:05PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-03-18 05:25PM  Edited Transcript of FLDM earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
09:25AM  Fluidigm (FLDM) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:05AM  Fluidigm: 2Q Earnings Snapshot Associated Press
Aug-02-18 04:05PM  Fluidigm Announces Second Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 08:30AM  Fluidigm Introduces a Lower-Cost Workflow for Full-Length Single-Cell mRNA Sequencing on C1 GlobeNewswire +5.96%
Jul-10-18 08:30AM  Fluidigm Announces First Multimodal Single-Cell Application for the C1 GlobeNewswire
Jul-05-18 04:05PM  Fluidigm Announces Conference Call and Webcast of Second Quarter 2018 Financial Results GlobeNewswire
Jun-29-18 10:59AM  Zacks.com featured highlights include: Hershey, Polaris, Lithia, Fluidigm and Univar Zacks
Jun-28-18 07:32AM  Bet on Rising P/E Investing With These 5 Top-Ranked Stocks Zacks
Jun-26-18 08:30AM  David King Joins Fluidigm as Vice President, Research and Development, Genomics GlobeNewswire
Jun-13-18 02:12PM  Edited Transcript of FLDM earnings conference call or presentation 3-May-18 9:00pm GMT Thomson Reuters StreetEvents
Jun-07-18 11:14AM  Fluidigm Corporations (NASDAQ:FLDM) Insiders Ramped Up Holdings Should You? Simply Wall St.
07:00AM  Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service GlobeNewswire
Jun-05-18 06:30AM  Fluidigm Releases Sample Identification Genotyping Panel for Translational and Clinical Research GlobeNewswire
May-11-18 07:10AM  Free Research Report as Thermo Fisher Scientifics Quarterly Revenue Surged 23%; Adjusted EPS Jumped 20% ACCESSWIRE
May-10-18 07:02PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-09-18 04:05PM  Fluidigm to Participate in Upcoming Investor Events GlobeNewswire
May-03-18 06:14PM  Fluidigm: 1Q Earnings Snapshot Associated Press +5.61%
04:04PM  Fluidigm Announces First Quarter Financial Results and Operational Progress GlobeNewswire
Apr-30-18 07:45AM  Report: Developing Opportunities within Fluidigm, MaxLinear, Southern National Bancorp of Virginia, Power Integrations, Hersha Hospitality Trust, and W.R. Berkley Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-23-18 08:00AM  Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations GlobeNewswire
Apr-19-18 08:42PM  Has Fluidigm Corporation (NASDAQ:FLDM) Improved Earnings Growth In Recent Times? Simply Wall St.
04:05PM  Fluidigm to Report Q1 2018 Financial Results and Host Conference Call GlobeNewswire
Apr-13-18 04:10PM  Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research GlobeNewswire
Apr-12-18 09:29AM  Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System GlobeNewswire
Mar-19-18 07:50AM  Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-13-18 08:54AM  What Investors Should Know About Fluidigm Corporations (NASDAQ:FLDM) Financial Strength Simply Wall St.
07:45AM  Fluidigm Announces Exchange of Convertible Notes GlobeNewswire
Mar-02-18 07:45AM  Fluidigm Announces Exchange of Convertible Notes GlobeNewswire -8.47%
Feb-27-18 05:03PM  What Should Investors Know About The Future Of Fluidigm Corporations (NASDAQ:FLDM) Business? Simply Wall St.
Feb-22-18 06:36PM  Edited Transcript of FLDM earnings conference call or presentation 8-Feb-18 10:00pm GMT Thomson Reuters StreetEvents -6.08%
Feb-15-18 07:30AM  Wired News Charles River Labs Inked an Agreement to Acquire MPI Research ACCESSWIRE +10.85%
Feb-14-18 04:05PM  Fluidigm to Participate in Upcoming Health Care Investor Conferences GlobeNewswire
07:20AM  Free Post Earnings Research Report: Thermo Fishers Quarterly Revenue Surged 22%; Adjusted EPS Advanced 16% ACCESSWIRE
Feb-08-18 09:07PM  Fluidigm reports 4Q loss Associated Press
04:05PM  Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Progress GlobeNewswire
12:50PM  Fluidigm Corporation to Host Earnings Call ACCESSWIRE
10:32AM  Is Fluidigm Corporation (NASDAQ:FLDM) Undervalued? Simply Wall St.
Jan-25-18 04:05PM  Fluidigm to Report Q4 and Full Year 2017 Financial Results GlobeNewswire
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARTHELEMY NICOLASDirectorMar 23Option Exercise0.002,500042,962Mar 26 05:49 PM
Paya Carlos VDirectorMar 23Option Exercise0.002,500036,856Mar 26 05:49 PM
Linthwaite Stephen ChristopherPresident & CEOFeb 20Option Exercise0.0012,5620156,102Feb 21 09:10 PM
Khadder NicholasSee RemarksFeb 20Option Exercise0.004,901036,829Feb 21 09:09 PM
McPhail StevenChief Commercial OfficerFeb 20Option Exercise0.003,722058,417Feb 21 09:08 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERFeb 20Option Exercise0.004,952037,421Feb 21 09:08 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 24Buy7.798566210,473,809Dec 26 03:40 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 20Buy7.425764,27310,413,365Dec 26 03:40 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 19Buy7.861281,00610,412,789Dec 20 05:07 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 18Buy7.713627810,412,661Dec 20 05:07 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 14Buy7.814132010,412,625Dec 18 03:09 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 12Buy6.751,000,0006,750,00010,404,641Dec 14 06:14 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 10Buy7.7235,000270,2009,970,342Dec 11 03:26 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 07Buy7.95332629,935,342Dec 11 03:26 PM
Linthwaite Stephen ChristopherPresident & CEONov 20Option Exercise0.0012,5620146,650Nov 21 09:07 PM
Khadder NicholasSee RemarksNov 20Option Exercise0.004,901032,530Nov 21 09:06 PM
McPhail StevenChief Commercial OfficerNov 20Option Exercise0.003,720052,055Nov 21 09:06 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERNov 20Option Exercise0.005,051034,217Nov 21 09:07 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorNov 14Buy7.5547,768360,6969,809,695Nov 16 03:01 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorNov 08Buy7.841279969,761,927Nov 13 03:42 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorNov 06Buy7.408556,3269,761,800Nov 08 03:00 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 26Buy7.192,59918,68011,337,342Oct 26 12:30 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 25Buy7.217,36353,09511,334,743Oct 26 12:30 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 19Buy7.5125,209189,23111,327,380Oct 23 04:19 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 12Buy7.451813411,302,171Oct 15 06:05 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 11Buy7.445339411,302,153Oct 15 06:05 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 09Buy7.2934,896254,21711,302,100Oct 11 04:31 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 01Buy7.562418111,267,204Oct 03 06:16 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 27Buy7.535239211,296,850Oct 01 03:19 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 25Buy7.982,94023,44711,296,798Sep 27 05:08 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 19Buy8.224032911,293,858Sep 21 03:00 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 11Buy8.421714311,465,884Sep 13 04:00 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 06Buy7.844938411,465,867Sep 07 03:21 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 05Buy7.851521,19311,465,818Sep 07 03:21 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorAug 30Buy7.861814111,465,666Sep 04 06:47 PM
Linthwaite Stephen ChristopherPresident & CEOAug 20Option Exercise0.0012,5620138,433Aug 22 05:00 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERAug 20Option Exercise0.005,051020,117Aug 22 05:01 PM
Khadder NicholasSee RemarksAug 20Option Exercise0.004,901016,022Aug 22 04:59 PM
McPhail StevenChief Commercial OfficerAug 20Option Exercise0.003,722038,002Aug 22 05:00 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorAug 15Buy6.7825,500172,88011,465,648Aug 17 01:23 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorAug 08Buy6.762114211,720,361Aug 10 02:46 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorAug 02Buy6.362918411,720,340Aug 06 03:41 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJul 31Buy6.402,69217,23011,720,311Aug 02 04:05 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJul 27Buy6.1420,029123,07111,717,619Jul 31 03:19 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJul 12Buy6.275433911,697,536Jul 16 02:07 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJul 03Buy6.006136611,697,536Jul 06 03:35 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 22Buy5.453418511,697,475Jul 06 03:35 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 19Buy4.7210,59349,96011,697,441Jun 21 07:31 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 18Buy4.7689,544426,08611,687,194Jun 19 08:50 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 15Buy4.9332,005157,89811,600,578Jun 19 08:50 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 13Buy4.95149,215738,74211,569,391Jun 14 06:28 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 12Buy5.005002,50011,422,857Jun 14 06:28 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 08Buy5.5140,763224,59711,422,357Jun 11 05:41 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorJun 07Buy5.5415,00083,03011,381,594Jun 11 05:41 PM
JONES PATRICK SDirectorMay 30Option Exercise0.008,000013,000Jun 01 08:57 PM
BARTHELEMY NICOLASDirectorMay 30Option Exercise0.008,000034,362Jun 01 08:56 PM
Burbach Gerhard FDirectorMay 30Option Exercise0.008,000032,115Jun 01 08:55 PM
COLELLA SAMUEL DDirectorMay 30Option Exercise0.008,000079,923Jun 01 08:55 PM
Paya Carlos VDirectorMay 30Option Exercise0.008,000023,734Jun 01 08:54 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 29Buy5.601,2006,71411,247,392May 31 05:36 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 25Buy5.662,87016,24411,251,041May 29 03:18 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 24Buy5.707,10040,44911,248,171May 29 03:18 PM
McPhail StevenChief Commercial OfficerMay 20Option Exercise0.002,396034,999May 22 09:02 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERMay 20Option Exercise0.002,800016,035May 22 09:02 PM
Linthwaite Stephen ChristopherPresident & CEOMay 20Option Exercise0.004,7500122,514May 22 09:02 PM
Khadder NicholasSee RemarksMay 20Option Exercise0.002,650010,978May 22 09:01 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 09Buy5.3716,90090,83611,241,071May 11 05:01 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 08Buy5.4733,000180,43111,226,078May 09 03:56 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 07Buy5.6044,700250,16411,196,801May 09 03:56 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 04Buy5.6889,800510,48211,158,071May 07 05:20 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorMay 03Buy5.852,40514,06911,081,432May 07 05:20 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorApr 30Buy5.926,64939,37011,079,027May 02 07:04 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorApr 26Buy5.969,60957,27111,072,378Apr 30 05:15 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorApr 25Buy5.922,40014,20611,062,769Apr 26 04:24 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorApr 24Buy5.951,3007,73311,060,369Apr 26 04:24 PM